Up­dat­ed: Apel­lis vows to be trans­par­ent about eye in­flam­ma­tion tied to Syfovre, but ques­tions re­main

Last year
R&D

FDA asks Citius for en­hanced prod­uct test­ing in CRL for non-Hodgkin lym­phoma drug Lym­phir

Last year
R&D

Af­ter EQRx stint, Ja­mi Ru­bin quick­ly re­turns to CFO post at start­up Bound­less Bio

Last year
People
Startups

Sum­it­o­mo and Ot­su­ka schiz­o­phre­nia as­set flunks PhI­II, com­pa­nies blame Covid-19 in­duced place­bo ef­fect

Last year
R&D

Bio­gen's $7.3B M&A deal, lay­offs; R&D shake­up at Pfiz­er, As­traZeneca; Scal­ing rare dis­ease meds; Q2 earn­ings; and ...

Last year
Weekly

Phar­ma gi­ants tout AI tools as high pri­or­i­ty in half-year earn­ings re­ports

Last year
AI
Pharma

Re­pub­li­cans share draft bill to ad­dress drug short­ages

Last year
Pharma
FDA+

Mer­ck touts topline PhI­II Keytru­da da­ta in pre-surgery breast can­cer treat­ment

Last year
R&D
Pharma

US gov­ern­ment to ac­quire $138M worth of Tpoxx dos­es

Last year
Pharma
Manufacturing

Want­ed: More phar­ma field med­ical teams, as study finds they can amp drug launch sales

Last year
Pharma
Marketing

Sanofi, BioN­Tech cut ear­ly-stage mR­NA can­cer ther­a­py from pipeline

Last year
R&D
Pharma

Io­n­is widens eplon­ter­sen agree­ment with As­traZeneca; In­ozyme looks to get $60M in pub­lic of­fer­ing

Last year
News Briefing

Alk­er­mes hikes up 2023 fi­nan­cials by $425M af­ter In­ve­ga li­cense fight win against John­son & John­son

Last year
Pharma

Ri­bon Ther­a­peu­tics rids pre­clin­i­cal work, trims staff to fo­cus on two clin­i­cal PARP in­hibitors

Last year
People
Startups

Bio­gen makes its move, an­nounc­ing a $7.3B deal for Rea­ta

Last year
Deals

Cyrus Moza­yeni fol­lows ADC 'bea­con' to Pheon CEO role; BeiGene los­es busi­ness chief to Te­va

Last year
Peer Review

As­traZeneca picks up Pfiz­er’s rare dis­ease gene ther­a­pies, taps new R&D leader as Mene Pan­ga­los steps down

Last year
People
Deals

Ho­mol­o­gy shut­ters de­vel­op­ment as ge­net­ic med­i­cines biotech flash­es ‘for sale’ sign, lays off 80 em­ploy­ees

Last year
People
R&D

Mer­ck touts pos­i­tive PhI­II re­sults for 21-va­lent pneu­mo­coc­cal vac­cine can­di­date

Last year
Pharma

Take­da re­veals PhII fail for rare ge­net­ic con­di­tion, looks to new prod­uct pipeline to bol­ster growth

Last year
R&D
Pharma

BMS looks to new prod­uct port­fo­lio as rev­enues slide due to Revlim­id loss­es

Last year
Pharma

NASH or MASH? Name changes to es­tab­lished con­di­tion stir up con­fu­sion in liv­er dis­ease com­mu­ni­ty

Last year
Pharma
Marketing

Man­u­fac­tur­ing roundup: Cu­ria se­cures deal with Touch­light; Gene-fo­cused Vec­tor­Builder hits ‘uni­corn sta­tus’

Last year
Manufacturing

Ako­rn’s bank­rupt­cy, re­calls bring a drug to treat lead poi­son­ing in­to short­age

Last year
R&D
Manufacturing
First page Previous page 304305306307308309310 Next page Last page
A service from the Financial Times